About Mankind Pharma Limited

Mankind Pharma Limited is one of India’s leading pharmaceutical companies, founded in 1991 and commencing operations in 1995. The Company develops, manufactures and markets a broad range of pharmaceutical formulations across acute and chronic therapies, along with consumer healthcare products including condoms, pregnancy detection kits, antacid powders, vitamin and mineral supplements, oral contraceptives and medicated anti-acne preparations.

The Company has established a strong domestic presence and expanded globally with subsidiaries in the US, Singapore, the UAE, Germany, Malaysia and the Philippines. A major milestone was the acquisition of Bharat Serums and Vaccines (BSV) in October 2024, strengthening its position in super-specialty therapies and women’s health. As on March 31, 2025, Mankind Pharma had 38 subsidiaries as per the consolidated financial statements.

Mankind operates 32 manufacturing facilities and 6 R&D centres, with more than 75% in-house manufacturing and over 95% local procurement of raw materials. The Company has an installed capacity of 44+ billion units and employs 5,100+ manufacturing staff and 730 scientists, including 73 PhDs. Its distribution is supported by 16,000+ stockists, a 17,700+ strong field force, and coverage of over 5 lakh doctors.

Business Segment of Mankind Pharma Limited

• Therapy-wise sales mix (FY 2024-25): Cardiovascular 15%, Anti-Infectives 14%, Gynaecology 10%, Gastrointestinal 10%, Anti-Diabetic 8%, VMN 8%, Respiratory 7%, Dermatology 5%, Urology 5%, Pain/Analgesics 4%, Neuro/CNS 2%, Others 10%. The top five therapies contributed 57% of overall sales.

• Geography: Domestic 87%, International 13%.

• Consumer Healthcare contributed 7% to overall business.

Mankind Pharma Limited’s Key Management Team

• Ramesh Juneja – Chairman & Whole Time Director

• Rajeev Juneja – Vice Chairman & Managing Director

• Sheetal Arora – Chief Executive Officer & Whole Time Director

• Satish Kumar Sharma – Whole Time Director

• Arjun Juneja – Chief Operating Officer

• Ashutosh Dhawan – Global Chief Financial Officer

• Hitesh Kumar Jain – Company Secretary & Compliance Officer (effective January 9, 2025)

Latest Updates on Mankind Pharma Limited

• Acquisition: The Company acquired 100% stake in Bharat Serums and Vaccines Limited on October 23, 2024, for ₹13,768 crore, consolidating its presence in critical care, fertility and super-specialty therapies.

• Digital transformation: Implemented initiatives such as PACE (procurement digitisation), Wave (distribution optimisation), and Superman SFA (GenAI-powered CRM), with IoT-enabled shopfloors and a Zero Trust cybersecurity framework.

• Awards and recognitions: Excellence in Pharma Environmental Sustainability Award, Golden Peacock OHS Award (Paonta Sahib Unit), ASSOCHAM Pharma Excellence Award, and Deal Maker Award (Business Today) for Ramesh Juneja.

• Product expansion: Entered the Gonadotrophins (IVF) segment via BSV acquisition, scaled PCOS and Iron portfolios, launched FCM in Gynaecology, and in-licensed brands such as Symbicort in Respiratory and advanced anti-infective injectables.